Journal
FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2022.868521
Keywords
cardiac rehabilitation; endothelial (dys)function; L-Arg; L-Arginine; frail adults; frailty; cognitive impairment
Categories
Funding
- National Institutes of Health (NIH): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK123259, R01-DK033823]
- National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (NHLBI) [R01-HL146691, T32-HL144456]
- National Institutes of Health (NIH): National Institute on Aging (NIA) [R56-AG066431]
- Irma T. Hirschl Trust
- Monique Weill-Caulier Trust
- Diabetes Action Research and Education Foundation
- FV hold postdoctoral fellowships from the American Heart Association [AHA-22POST915561, AHA-21POST836407]
Ask authors/readers for more resources
This study aimed to verify the effects of L-Arginine on global cognitive function in hypertensive frail older adults. The results showed a significant difference in the Montreal Cognitive Assessment test score between the L-Arginine treated group and placebo, indicating that L-Arginine supplementation significantly improved cognitive impairment. It was also demonstrated that L-Arginine attenuated mitochondrial oxidative stress in human endothelial cells.
Cognitive impairment is a prevailing event in hypertensive patients and in frail older adults. Endothelial dysfunction has been shown to underlie both hypertension and cognitive dysfunction. Our hypothesis is that L-Arginine, which is known to ameliorate endothelial dysfunction, could counteract cognitive impairment in a high-risk population of hypertensive frail older adults. We designed a clinical trial to verify the effects of 4-weeks oral supplementation of L-Arginine on global cognitive function of hypertensive frail older patients. The study was successfully completed by 35 frail hypertensive elderly patients assigned to L-Arginine and 37 assigned to placebo. At follow-up, we found a significant difference in the Montreal Cognitive Assessment (MoCA) test score between the L-Arginine treated group and placebo (p: 0.0178). Moreover, we demonstrated that L-Arginine significantly attenuates Angiotensin II-induced mitochondrial oxidative stress in human endothelial cells. In conclusion, our findings indicate for the first time that oral L-Arginine supplementation significantly improves cognitive impairment in frail hypertensive older adults.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available